



Dependable Partners for
Development with Growth





About Us

ZCL Chemicals Ltd is one of the fastest growing Pharmaceutical companies in India that combines the power of Science & Technology. Established in 1991, ZCL Chemicals Ltd (ZCL) is Head quartered in Mumbai. The cGMP-manufacturing facility and state-of-the art R&D Center are located in the Industrial park of Ankleshwar in Gujarat State.

Develops and manufactures Active Pharmaceutical Ingredients (APIs) & Intermediates and offers Contract Manufacturing and other services.

An ISO 9001, ISO 14001 and OHSAS 18001 certified company with the manufacturing facility successfully inspected/ audited by the US FDA (2010 and 2014), KFDA (2014), WHO-GMP and some of the leading Pharmaceutical companies.



Manufacturing

Strategically located at Ankleshwar, Gujarat which is 192 miles/320 km North of Mumbai.

- Three Multi-purpose cGMP Manufacturing plants
- Installed Reaction capacity 107 KL; 21 Stainless Steel reactors, 22 Glass Lined reactors ranging from 100 L to 8,000 L
- 16 Centrifuges – Stainless Steel and halar-coated
- 14 Dryers – RCVD, VTD, FBD, TD and Nauta
- Reaction Temperature ranging from -25 deg C to +220 deg C
- High vacuum distillation at 1 Torr and high pressure reactions at 5 Bar

Customer-centric approach

ZCL's customer-centric approach has won the status of preferred supplier and strategic partner from Global Pharmaceutical companies. 70% of revenue share is from the business with the major Innovators.

Geographical spread:

Established Markets: 94%

Emerging Markets (Including India): 6%

New API facility

ZCL is on an expansion mode to set up a modern multi-purpose, multi-product API in the existing site at Ankleshwar (Gujarat, India). The facility will take care of small trials up to full commercial scale production for partners/customers world-wide.

- To be operational by May 2016

- The state-of-the-art plant is designed to conform to cGMP as well as US FDA, EU GMP, TGA, ANVISA, PMDA, WHO guidelines besides meeting local FDA guidelines.
- The plant is also designed to meet OHSAS and ISO guidelines on EHS and Quality.
- Production Capacity: 104 KL
- Three dedicated Streams of final Crystallization with Powder Processing areas
- Operating temperature: -70 deg C to +220 deg C



Reaction Capabilities

- Acylation and Alkylation
- Asymmetric transformation
- Azide synthesis
- Bromination
- Chiral separations
- Chlorosulfonation
- Coupling reaction (Heck, Stille)
- Cyclization
- Decarboxylation
- Epoxidation
- Friedel-Craft
- Grignard
- Hydrolysis
- Oxidation
- Phase Transfer Catalysis
- Reductions - by chemical and catalytical methods
- Reductive Amination
- Ritter reaction
- Sandmeyer reaction
- Solid distillation (Upto 0.01 torr)
- Ullmann Reaction
- Willgerodt Reaction

Research & Development

Located in our Ankleshwar facility. State-of-the-art R&D Centre has four furnished labs equipped with some of the latest analytical equipment and managed by experienced scientists and qualified professionals.

- Proven track record for developing complex and quality products
- Expertise in developing non-infringing processes (20 process patents)
- Collaborative research and development under confidentiality agreements
- Seamless interface with operations resulting in credible deliverance



Quality Systems

- Successfully inspected by USFDA and KFSA
- Adherence to ICH Q7A & ISO 9001 quality standards.
- Regular Customer Audits – most of them being global pharmaceutical companies.
- Well-equipped instrumentation labs
- Microbiology lab meeting Schedule M requirements

Active Pharma Ingredients (APIs)

Product	Status	Pharmacoepeia	CAS No.	Therapeutic Use
Alprazolam	Tech pack	USP/EP	28981-97-7	Anxiolytic
Aripiprazole	USDMF & CEP	USP/EP	129722-12-9	Anti-depressant/Anti-psychotic
Atomoxetine HCl	CEP+, USDMF & TDMF	USP/EP	82248-59-7	Attention Deficit Hyperactivity Disorder (ADHD)
Betahistine Dihydrochloride [^]	CEP	USP/BP/EP/IP	5579-84-0	Vertigo
Betahistine Mesylate	Tech pack	EP/JP/IP	54856-23-4	Vertigo
Cilostazol	Tech pack	USP	73963-72-1	Anti-thrombotic, Anti-platelet agent
Clozapine	USDMF* & CEP*	USP/EP/IP	5786-21-0	Anti-psychotic
Dexmethylphenidate HCl	Tech pack	Inhouse	19262-68-1	Attention Deficit Hyperactivity Disorder (ADHD)
Felbinac [^]	EDMF* & JDMF*	BP/EP/JP	5728-52-9	Anti-inflammatory
Flupirtine Maleate	Tech pack	EP	75507-68-5	Analgesic
Fluvoxamine Maleate [^]	CEP, USDMF & TDMF	USP/BP/EP/IP/JP	61718-82-9	Anti-depressant
Guanfacine HCl	Tech pack	USP	29110-48-3	Attention Deficit Hyperactivity Disorder (ADHD), Hypertension
Levomepromazine Maleate [^]	CEP*	EP	7104-38-3	Anti-psychotic
Loxoprofen sodium	Tech pack	JP	80382-23-6	Anti-inflammatory, Analgesic
Memantine HCl [^]	USDMF	USP	41100-52-1	Alzheimer Disease
Methylphenidate HCl	Tech pack	USP/EP	298-59-9	Attention Deficit Hyperactivity Disorder (ADHD)
Modafinil	Tech pack	USP/EP	68693-11-8	CNS Stimulant
Olanzapine	USDMF*	USP	132539-06-1	Anti-psychotic
Oxazepam	Tech pack	EP	604-75-1	Anxiolytic
Quetiapine Fumarate	USDMF* & CEP*	USP/EP	111974-72-2	Anti-psychotic
Trifluoperazine HCl	Tech pack	USP/BP/EP/IP	440-17-5	Anti-psychotic
Zaltoprofen	KDMF	JP	74711-43-6	Anti-inflammatory
Zonisamide	Tech pack	USP/EP	68291-97-4	Anti-convulsant

Under Scale-up/New Development

Bromazepam	Under Scale up	EP	1812-30-2	Anxiolytic
Lurasidone HCl	Under Scale up	In-house	367514-88-3	Anti-psychotic
Rivaroxaban	Under Scale up	In-house	366789-02-8	Anti-coagulant
Dapagliflozin	Under development	In-house	461432-26-8	Anti-diabetic
Empagliflozin	Under development	In-house	864070-44-0	Anti-diabetic
Eslicarbazepine Acetate	Under development	In-house	236395-14-5	Anti-epileptic
Mirabegron	Under development	In-house	223673-61-8	Treatment of overactive bladder
Pirfenidone	Under development	In-house	53179-13-8	Anti-Inflammatory / Anti-Rheumatic

* Under filing ^ Written confirmation available + Applied

Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.

Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

February 2016

Active Pharma Ingredients (APIs) for North America

Product	Status	Pharmacoepeia	CAS No.	Therapeutic Use
Aripiprazole	USDMF* & EDMF*	USP	129722-12-9	Anti-depressant/Anti-psychotic
Atomoxetine HCl	USDMF & CEP	USP/EP	82248-59-7	Attention Deficit Hyperactivity Disorder (ADHD)
Betahistine Dihydrochloride ^	CEP #	USP/BP/EP/IP	5579-84-0	Vertigo
Cilostazol	Tech pack	USP	73963-72-1	Anti-thrombotic, Anti-platelet agent
Clozapine	CEP*	USP/EP	5786-21-0	Anti-psychotic
Felbinac^	EDMF* & JDMF*	BP/EP/IP	5728-52-9	Anti-inflammatory
Fluvoxamine Maleate^	CEP, USDMF & TDMF	USP/BP/EP/IP/JP	61718-82-9	Anti-depressant
Guanfacine HCl	Tech pack	USP	29110-48-3	Attention Deficit Hyperactivity Disorder (ADHD) Hypertension
Levomepromazine Maleate ^	CEP*	EP	7104-38-3	Antipsychotic
Memantine HCl	USDMF	USP	41100-52-1	Alzheimer Disease
Modafinil	Tech pack	USP/EP	68693-11-8	CNS Stimulant
Olanzapine	USDMF*	USP	132539-06-1	Anti-psychotic
Oxazepam	Tech pack	EP	604-75-1	Anxiolytic
Quetiapine Fumarate	USDMF* & CEP*	USP/EP	111974-72-2	Anti-psychotic
Trifluoperazine HCl	Tech pack	USP/BP/EP/IP	440-17-5	Anti-psychotic
Zonisamide	Tech pack	USP/EP	68291-97-4	Anti-convulsant

Under Scale-up/New Development

Lurasidone hydrochloride	Under Scale up	In-house	367514-88-3	Anti-psychotic
Rivaroxaban	Under Scale up	In-house	366789-02-8	Anti-coagulant
Dapagliflozin	Under development	In-house	461432-26-8	Anti-diabetic
Empagliflozin	Under development	In-house	864070-44-0	Anti-diabetic
Eslicarbazepine Acetate	Under development	In-house	236395-14-5	Anti-epileptic
Mirabegron	Under development	In-house	223673-61-8	Treatment of overactive bladder
Pirfenidone	Under development	In-house	53179-13-8	Anti-Inflammatory / Anti-Rheumatic

* Under filing # NDC Number available ^ Written confirmation available













Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.












Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

February 2016


Advanced Intermediates

Product	CAS No.	End Use	Structure
7-Hydroxy-3, 4-dihydroquinolin-2(1H)-one	22246-18-0	Aripiprazole	
(1H)-7-(4'-bromobutoxy)-3,4-dihydro-2-quinolinone	1297225-34-5	Aripiprazole	
1-(2,3-Dichlorophenyl) Piperazine HCl	119532-26-2	Aripiprazole	
3-(methylamino)-1-phenylpropan-1-ol	42142-52-9	Atomoxetine Fluoxetine Nisoxetine	
Chloromethyl cyclopropane	5911-08-0	Buprenorphine	
Bromomethyl cyclopropane	7051-34-5	Buprenorphine	
N-Benzhydrylpiperazine	841-77-0	Cinnarizine	
Benzenesulfonamide, 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)	169280-56-2	Darunavir	
Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-,1,1-dimethylethylester	191226-98-9	Darunavir	
Benzenesulfonamide, N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)-4-nitro	251105-80-3	Darunavir	
N-(1,4-Benzodioxan-2-carbonyl)-piperazine	70918-00-2	Doxazosin	
4-Hydroxy-3, 5-dimethyl benzonitrile	4198-90-7	Etravirine	






Advanced Intermediates

Product	CAS No.	End Use	Structure
4,4'-Difluorobenzhydrylpiperazine	27469-60-9	Flunarizine	
(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine	61747-22-6	Fluvoxamine	
2-Bromo-4'-benzyloxy-3'-nitroacetophenone	43229-01-2	Formoterol	
2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one	252964-68-4	Itraconazole	
1-Acetyl-4-(4-hydroxyphenyl) piperazine	67914-60-7	Ketoconazole	
(S)-1-chloro-3-[(4-chloro-E-benzylidene)-amino]-propan-2-ol	1345879-87-9	Linezolid	
2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid	68767-14-6	Loxoprofen Sodium	
2-Methyl-10H-thieno[2,3-b][1,5] benzo diazepine-4-amine HCl	138564-60-0	Olanzapine	
5-methyl-2-(2-nitrophenylamino) thiophene-3-carbonitrile	138564-59-7	Olanzapine	
N-Isopropyl-4-(4-hydroxyphenyl)-piperazine	67914-97-0	Terconazole	
2-(Trifluoromethyl)-phenothiazine	92-30-8	Trifluoperazine	

Intermediate for controlled substances

Product	CAS No.	End Use	Structure
N-[1-(benzyl)-4-(methoxymethyl)-4-piperidinyl]-N-phenyl Propanamide oxalate	61086-13-3	Alfentanil & Sufentanil	
1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one	84501-67-7	Alfentanil	
N-[(4-methoxymethyl-1-benzyl)-4-piperidinyl]-N-phenyl propanamide monohydrochloride	84255-05-0	Alfentanil & Sufentanil	
N-[4-(methoxymethyl)-piperidine-4-yl]-N-phenyl propanamide monohydrochloride	84196-16-7	Alfentanil & Sufentanil	
N-(1-Benzylpiperidin-4-yl)-N-phenylpropanamide Hydrochloride	5156-58-1	Fentanil	
N-[(4-Methoxymethyl)-4-piperidinyl]-N-phenyl propanamide	61086-18-8	Sufentanil	

Methyl Phenidate Series

Product	CAS No.	Structure
Phenyl-(2-pyridyl acetamide)	7251-52-7	
Phenyl-2-(2'-piperidyl)acetamide	19395-39-2	
Threo phenyl-2-piperidyl acetamide*	50288-62-5	
dl-threo ritalinic acid*	19395-41-6	
d-threo ritalinic acid hydrochloride*	82993-81-5	

*USDMF available














February 2016

Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.

Patented Products are available for R&D use as per permitted under 35 USC § 271 (e) (1)

Under Scale-up / New Development

Product	CAS No.	End Use	3-4 Months	Structure
1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, 2,3,4,6-tetraacetate, (1S)- D-Glucitol	461432-25-7	Dapagliflozin propanediol	Under development	
α -D-Glucopyranoside, methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, 2,3,4,6-tetraacetate	714269-58-6	Dapagliflozin propanediol	Under development	
(10S)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide	104746-04-5	Eslicarbazepine acetate	Under development	
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide	29331-92-8	Eslicarbazepine acetate	Under development	
1-Bromo-3,5-dimethyladamantane	941-37-7	Memantine HCl	Under development	
2-Chloro-1-Dimethylaminopropane HCl	4584-49-0	Methadone	Under development	
(1R)-2-[[2-(4-aminophenyl)ethyl]amino]-1-phenylethanol hydrochloride	521284-22-0	Mirabegron	Under development	
(1R)-2-[[2-(4-nitrophenyl)ethyl]amino]-1-phenylethanol	223673-34-5	Mirabegron	Under development	
2-(2-[3-(3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl)-3-hydroxy-n-propyl]phenyl)-2-propan-1-ol	142569-70-8	Montelukast	Under scale-up	
1-Aminoindan	34698-41-4	Rasagiline	Under scale-up	
4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride	898543-06-1	Rivaroxaban	Under scale-up	
2-(((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)-1H-isoindole-1,3(2H)-dione	446292-08-6	Rivaroxaban	Under scale-up	
1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one	6969-71-7	Trazodone	Under scale-up	

Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.

Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

February 2016



Environment, Health, Safety & Sustainability (EHS&S)

We aim to use natural resources efficiently and minimize the environmental impacts of our activities and products during their life cycles.

- ISO 14001 and OHSAS 18001 certified facility.
- Multiple effect evaporator and reverse osmosis facility.
- Recycle waste water treatment facility aiming towards ZERO discharge.
- HAZOP studies of processes after development.
- Emergency response measures to control and limit the impact of incidents.
- Compliant with state & local EHS regulations.
- EHS practices approved by Big Pharmaceutical companies.
- Member of EcoVadis, Rx-360 and CDP Supply Chain Program.

We are committed to

- Manufacture and supply safe and high quality products to meet customers' needs and expectations.
- Provide comfortable and safe workplace for employees as well as our associates and third party personnel.
- Enhance quality, environment, health and safety standards.
- Strengthen our Corporate Social Obligation (CSO) initiatives.

Registered Office

ZCL Chemicals Ltd.

C Wing, 819-821 , 215 Atrium,
Andheri Kurla Road, Chakala,
Andheri (E), Mumbai- 400093, India

Tel: +91 22 61539999
Fax: +91 22 61539997
Email: enquiries@zclchemicals.com

Manufacturing

ZCL Chemicals Ltd.

Plot No. 3102/B, G.I.D.C.,
Ankleshwar - 393 002
Gujarat - India.